Design, pharmacology, and toxicology of a novel chemically modified siRNA targeting hepatic angiotensinogen

This publication has 34 references indexed in Scilit:

• AttSiOff: a self-attention-based approach on siRNA design with inhibition and off-target effect prediction
  Med-X, 2024
• RNA Interference With Zilebesiran for Mild to Moderate Hypertension
  JAMA, 2024
• Therapeutic siRNA: State-of-the-Art and Future Perspectives
  BioDrugs, 2022
• Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants
  The Lancet, 2021
• Global burden of 87 risk factors in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019
  The Lancet, 2020
• Comprehensive Structure–Activity Relationship of TriantennaryN-Acetylgalactosamine Conjugated Antisense Oligonucleotides for Targeted Delivery to Hepatocytes
  Journal of Medicinal Chemistry, 2016
• Targeted In Vivo Delivery of siRNA and an Endosome-Releasing Agent to Hepatocytes
  2014
• siRNA vs. shRNA: Similarities and differences
  Advanced Drug Delivery Reviews, 2009
• Aliskiren, the First Renin Inhibitor for Treating Hypertension: Reactive Renin Secretion May Limit Its Effectiveness
  American Journal of Hypertension, 2007
• Design and Synthesis of Novel Amphiphilic Dendritic Galactosides for Selective Targeting of Liposomes to the Hepatic Asialoglycoprotein Receptor
  Journal of Medicinal Chemistry, 1999